|
|
|
|
|
|
|
|
|
|
financial news
Source: Sydys Corporation
SEATTLE, May 18, 2016 (GLOBE NEWSWIRE) -- Sydys
Corporation (OTCQB:SYYC), a clinical stage biotechnology company focused
on the development of immunotherapies, today announced the publication
of findings from a study demonstrating the potential of CVac™ in ovarian
cancer in the Journal for ImmunoTherapy of Cancer.
The study entitled “Progression-free
and overall survival in ovarian cancer patients treated with CVac™, a
mucin 1 dendritic cell therapy in a randomized Phase 2b trial was
led by Dr Heidi Gray at the University of Washington Medical Center, WA,
USA with Dr Jeffrey C Goh of Greenslopes Private Hospital, Queensland,
Australia and included several universities and institutions in the
United States and Australia (NCT01068509), including;
- Scripps Cancer Center, San Diego, CA
- Peter MacCallum Cancer Centre, East Melbourne Vic, Australia
- Cleveland Clinic Foundation, Cleveland, OH
- Duke Cancer Institute, Duke University Health System, Durham, NC
- University of California, San Francisco & Sutter Health Research Institute, San Francisco, CA
- Stanford University Cancer Institute, Stanford, CA
The
publication outlines results obtained from a Phase 2b clinical trial
evaluating the safety, efficacy and immune outcomes of CVac™ in patients
with advanced epithelial ovarian cancer.
The
randomized, open label trial enrolled 56 patients undergoing first or
second clinical remission. Twenty seven patients received the standard
of care, while 20 patients received CVac™, a mucin 1 targeted-dendritic
cell (DC) treatment as a maintenance therapy, over a period of 56 weeks.
The primary endpoint was efficacy measure through progression free
survival (PFS), while the secondary endpoint included overall survival
(OS).....
0 comments :
Post a Comment
Your comments?